Cited 15 times in
Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박윤수 | - |
dc.contributor.author | 송영구 | - |
dc.contributor.author | 안진영 | - |
dc.contributor.author | 최준용 | - |
dc.contributor.author | 이경화 | - |
dc.contributor.author | 김용찬 | - |
dc.date.accessioned | 2022-12-22T04:38:49Z | - |
dc.date.available | 2022-12-22T04:38:49Z | - |
dc.date.issued | 2022-10 | - |
dc.identifier.issn | 1198-743X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/192184 | - |
dc.description.abstract | Objectives: We assessed humoral responses and reactogenicity following the heterologous vaccination compared to the homologous vaccination groups. Methods: We enrolled healthcare workers (HCWs) who were either vaccinated with ChAdOx1 followed by BNT162b2 (heterologous group) or 2 doses of ChAdOx1 (ChAdOx1 group) or BNT162b2 (BNT162b2 group). Immunogenicity was assessed by measuring antibody titers against receptor-binding domain (RBD) of SARS-CoV-2 spike protein in all participants and neutralizing antibody titer in 100 participants per group. Reactogenicity was evaluated by a questionnaire-based survey. Results: We enrolled 499 HCWs (ChAdOx1, n = 199; BNT162b2, n = 200; heterologous ChAdOx1/BNT162b2, n = 100). The geometric mean titer of anti-receptor-binding domain antibody at 14 days after the booster dose was significantly higher in the heterologous group (11 780.55 binding antibody unit (BAU)/mL [95% CI, 10 891.52-12 742.14]) than in the ChAdOx1 (1561.51 [95% CI, 1415.03-1723.15]) or BNT162b2 (2895.90 [95% CI, 2664.01-3147.98]) groups (both p < 0.001). The neutralizing antibody titer of the heterologous group (geometric mean ND50, 2367.74 [95% CI, 1970.03-2845.74]) was comparable to that of the BNT162b2 group (2118.63 [95% CI, 1755.88-2556.32]; p > 0.05) but higher than that of the ChAdOx1 group (391.77 [95% CI, 326.16-470.59]; p < 0.001). Compared with those against wild-type SARS-CoV-2, the geometric mean neutralizing antibody titers against the Delta variant at 14 days after the boosting were reduced by 3.0-fold in the heterologous group (geometric mean ND50, 872.01 [95% CI, 685.33-1109.54]), 4.0-fold in the BNT162b2 group (337.93 [95% CI, 262.78-434.57]), and 3.2-fold in the ChAdOx1 group (206.61 [95% CI, 144.05-296.34]). The local or systemic reactogenicity after the booster dose in the heterologous group was higher than that of the ChAdOx1 group but comparable to that of the BNT162b2 group. Discussion: Heterologous ChAdOx1 followed by BNT162b2 vaccination with a 12-week interval induced a robust humoral immune response against SARS-CoV-2, including the Delta variant, that was comparable to the homologous BNT162b2 vaccination and stronger than the homologous ChAdOx1 vaccination, with a tolerable reactogenicity profile. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Elsevier | - |
dc.relation.isPartOf | CLINICAL MICROBIOLOGY AND INFECTION | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antibodies, Neutralizing* | - |
dc.subject.MESH | Antibodies, Viral | - |
dc.subject.MESH | BNT162 Vaccine | - |
dc.subject.MESH | COVID-19* / prevention & control | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | SARS-CoV-2 / genetics | - |
dc.subject.MESH | Spike Glycoprotein, Coronavirus | - |
dc.subject.MESH | Vaccination | - |
dc.title | Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Seongman Bae | - |
dc.contributor.googleauthor | Jae-Hoon Ko | - |
dc.contributor.googleauthor | Ju-Yeon Choi | - |
dc.contributor.googleauthor | Woo-Jung Park | - |
dc.contributor.googleauthor | So Yun Lim | - |
dc.contributor.googleauthor | Jin Young Ahn | - |
dc.contributor.googleauthor | Kyoung-Ho Song | - |
dc.contributor.googleauthor | Kyoung Hwa Lee | - |
dc.contributor.googleauthor | Young Goo Song | - |
dc.contributor.googleauthor | Yong Chan Kim | - |
dc.contributor.googleauthor | Yoon Soo Park | - |
dc.contributor.googleauthor | Won Suk Choi | - |
dc.contributor.googleauthor | Hye Won Jeong | - |
dc.contributor.googleauthor | Shin-Woo Kim | - |
dc.contributor.googleauthor | Ki Tae Kwon | - |
dc.contributor.googleauthor | Eun-Suk Kang | - |
dc.contributor.googleauthor | Ah-Ra Kim | - |
dc.contributor.googleauthor | Sundong Jang | - |
dc.contributor.googleauthor | Byoungguk Kim | - |
dc.contributor.googleauthor | Sung Soon Kim | - |
dc.contributor.googleauthor | Hee-Chang Jang | - |
dc.contributor.googleauthor | Jun Yong Choi | - |
dc.contributor.googleauthor | Sung-Han Kim | - |
dc.contributor.googleauthor | Kyong Ran Peck | - |
dc.identifier.doi | 10.1016/j.cmi.2022.04.019 | - |
dc.contributor.localId | A01598 | - |
dc.contributor.localId | A02037 | - |
dc.contributor.localId | A02267 | - |
dc.contributor.localId | A04191 | - |
dc.contributor.localId | A04620 | - |
dc.contributor.localId | A00752 | - |
dc.relation.journalcode | J00587 | - |
dc.identifier.eissn | 1469-0691 | - |
dc.identifier.pmid | 35598855 | - |
dc.subject.keyword | BNT162b2 | - |
dc.subject.keyword | COVID-19 | - |
dc.subject.keyword | ChAdOx1 | - |
dc.subject.keyword | Heterologous vaccination | - |
dc.subject.keyword | SARS-CoV-2 | - |
dc.contributor.alternativeName | Park, Yoon Soo | - |
dc.contributor.affiliatedAuthor | 박윤수 | - |
dc.contributor.affiliatedAuthor | 송영구 | - |
dc.contributor.affiliatedAuthor | 안진영 | - |
dc.contributor.affiliatedAuthor | 최준용 | - |
dc.contributor.affiliatedAuthor | 이경화 | - |
dc.contributor.affiliatedAuthor | 김용찬 | - |
dc.citation.volume | 28 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1390.e1 | - |
dc.citation.endPage | 1390.e7 | - |
dc.identifier.bibliographicCitation | CLINICAL MICROBIOLOGY AND INFECTION, Vol.28(10) : 1390.e1-1390.e7, 2022-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.